

Content

Editorial	15
1. The history of gastric cancer	17
<i>Florian Lordick, Masanori Terashima, Jörg Rüdiger Siewert</i>	
1.1 Summary	17
1.2 Gastric cancer from the ancient world until the Middle Ages	17
1.3 Gastric cancer in the early modern period	19
1.4 The beginning of modern gastric cancer treatment	20
1.5 Recent developments and clinical-scientific achievements	23
1.6 The Asian perspective	25
1.7 Perspective	26
2. Epidemiology of oesophageal and gastric cancers	29
<i>Ondrej Majek, Denisa Krejci, Tomas Pavlik, Jan Muzik, Ladislav Dusek</i>	
2.1 Introduction	29
2.2 International comparison of the incidence and mortality of oesophageal and gastric cancers	30
2.3 Cancer control information system in the Czech Republic	32
2.4 Oesophageal cancer in the Czech Republic	34
2.5 Gastric cancer in the Czech Republic	43
2.6 Conclusion	52
3. TNM classification of tumours of the oesophagogastric junction and stomach	55
<i>Christian W. Wittekind</i>	
3.1 Introduction	55
3.2 TNM of stomach tumours	56
3.3 Summary of changes in the eighth edition of the TNM classifications	56
3.4 When to classify tumours of the OGJ as oesophageal tumours and when as stomach tumours?	56
3.5 Definition of the regional lymph nodes of tumours of the OGJ	58
3.6 TNM classification of tumours of the oesophagus including OGJ	58
3.7 Tumours of the stomach	61
3.8 TNM classification of neoadjuvantly treated tumours – use of the prefix “Y”	64
3.9 Future fields with a potential for changes of TNM classification of stomach tumours	65
3.10 The future and open question	66

4. Pathology of gastric cancer: diagnostic, prognostic and predictive markers in oesophageal and gastric cancer	69
<i>Ales Ryska</i>	
4.1 Introduction	69
4.2 Pathology of gastric cancer	69
4.3 Prognostic and predictive markers	78
5. Molecular characterisation and microbiome of gastric cancer	91
<i>Elizabeth Smyth</i>	
5.1 Introduction	91
5.2 Molecular classification systems for gastric and oesophagogastric cancer	91
5.3 The Cancer Genome Atlas gastric cancer subtypes	92
5.4 Asian Cancer Research Group subtypes	93
5.5 Oesophagogastric cancer signatures	94
5.6 Clinical utility of TCGA subgroups	94
5.7 Specific molecular subgroups: microsatellite unstable gastric cancer	95
5.8 The immune microenvironment in gastric cancer	96
5.9 Prognostic and predictive gene signatures	97
5.10 Molecular heterogeneity as a challenge in gastric cancer	98
5.11 Circulating tumour DNA in gastric cancer	99
5.12 The microbiome and gastric cancer	99
6. Barrett's oesophagus	105
<i>Jan Martinek, Zuzana Rabekova</i>	
6.1 Introduction and historical remarks	105
6.2 Definition of Barrett's oesophagus	106
6.3 Origin of metaplastic cells and molecular alterations in patients with Barrett's oesophagus	106
6.4 Epidemiology, risk factors and population screening	108
6.5 Risk of oesophageal adenocarcinoma (table 6.2)	109
6.6 Surveillance of patients with Barrett's oesophagus	110
6.7 Endoscopy in patients with Barrett's oesophagus	111
6.8 Treatment of patients with Barrett's oesophagus	115
7. Staging in oesophageal and gastric cancer – diagnostic endoscopy and imaging	125
<i>Stepan Suchanek, Pavel Fencel</i>	
7.1 Diagnostic endoscopy	125
7.2 The role of diagnostic imaging in carcinoma of the oesophagus and stomach	130

8. Endoscopic treatment for early gastric cancer	137
<i>Ondrej Urban</i>	
8.1 Introduction	137
8.2 Indication for endoscopic resection of EGC	138
8.3 Methods of endoscopic resection	139
8.4 Handling of resected specimen and risk of lymph node metastasis assessment	143
8.5 Curability of endoscopic resection	145
8.6 Follow-up after endoscopic treatment	145
8.7 The role of endoscopic treatment in the therapeutic algorithm of EGC	146
9. Surgery for oesophageal cancer	149
<i>Tomas Harustiak, Robert Lischke</i>	
9.1 Introduction	149
9.2 Position of surgery in the multidisciplinary management of oesophageal cancer	149
9.3 Preoperative evaluation	151
9.4 Principles of surgery	153
9.5 Surgical procedures	162
9.6 Surgical strategies for adenocarcinoma of the oesophagogastric junction	164
9.7 Postoperative management	165
9.8 Postoperative complications and short-term results	166
9.9 Long-term outcomes and quality of life after oesophagectomy	168
9.10 Conclusion	169
10. Minimally invasive surgery for oesophageal cancer – benefits and controversies	173
<i>Magnus Nilsson</i>	
10.1 Introduction and history	173
10.2 Types of MIO	174
10.3 MIO vs. open oesophagectomy	179
10.4 Learning MIO	180
10.5 Future perspectives	181
11. Surgery of gastric cancer	183
<i>Vaclav Jedlicka, Libor Nemeč, Roman Seřr</i>	
11.1 Introduction and historical remarks	183
11.2 Indications for surgical resection for gastric cancer	183
11.3 Types of surgery	184
11.4 Surgical techniques	185
11.5 Morbidity and mortality of gastrectomy	195
11.6 Perioperative and postoperative management	196
11.7 ERAS	197
11.8 Postoperative quality of life	198
11.9 Summary	199

12. Laparoscopic and robot-assisted surgery for gastric cancer	205
<i>Satoshi Kamiya, Rie Makuuchi, Masanori Terashima</i>	
12.1 Introduction	205
12.2 Laparoscopic gastrectomy for gastric cancer	206
12.3 Robot-assisted gastrectomy for gastric cancer	215
12.4 Future perspectives	219
12.5 Conclusion	220
13. Perioperative care in oesophageal cancer	225
<i>Jiri Dvorsky</i>	
13.1 Introduction	225
13.2 Epidemiology	225
13.3 Preoperative period	225
13.4 Intraoperative period	230
13.5 Postoperative period	231
13.6 Conclusion	231
14. Management of locally advanced oesophagogastric cancer	235
<i>Radka Obermannova, Renata Soumarová, Peter Grell</i>	
14.1 Introduction	235
14.2 Perioperative chemotherapy	240
14.3 Chemoradiation in resectable gastric and OGJ cancer	245
14.4 Adjuvant chemotherapy in gastric cancer	247
14.5 Individualised and randomised approaches in gastric cancer	248
14.6 Conclusions	250
15. Management of metastatic gastric cancer	255
<i>Milada Zemanova, Peter Grell, Radka Obermannova</i>	
15.1 Introduction	255
15.2 Systemic therapy	255
15.3 First-line systemic treatment	256
15.4 Second-line	261
15.5 Third-line and beyond	262
15.6 Oligometastatic disease	262
15.7 Conclusions	264
16. Vanishing molecules in oesophagogastric cancer treatment	269
<i>Florian Lordick</i>	
16.1 Introduction: optimism and failures in oesophagogastric drug development	269
16.2 Targeting activated signal transduction	270
16.3 Targeting tumour angiogenesis	274
16.4 Targeting DNA mismatch repair	275
16.5 Targeting the immune system	276
16.6 Summary	277

17. Immunotherapy with checkpoint inhibitors shows solid activity in advanced oesophageal and gastric cancers	281
<i>Markus Moehler, Katrin Goepfert</i>	
17.1 Introduction	281
17.2 Importance of cellular immune defence	281
17.3 Results for ICI for oesophageal carcinoma	284
17.4 Results for ICI for gastric/oesophagogastric junction cancer	286
17.5 Maintenance approaches	287
17.6 New ways to amplify anti-tumour immune response	288
17.7 Biomarkers for the effectiveness of immunotherapy	289
17.8 Outlook	290
Abbreviations	295
Index	299
Summary	311
Authors	315
List of authors	331